GRAIL
Founded Year
2016Stage
Acquired | AcquiredTotal Raised
$2.005BValuation
$0000About GRAIL
GRAIL develops technologies for early cancer detection. Its product includes Galleri which provides multi-cancer early detection tests. GRAIL was formerly known as PSC15. The company was founded in 2016 and is based in Menlo Park, California. In August 2021, GRAIL was acquired by Illumina.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Research containing GRAIL
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned GRAIL in 7 CB Insights research briefs, most recently on Jun 2, 2022.
Dec 1, 2020
Can Applying AI To Genomics Improve Healthcare?
Expert Collections containing GRAIL
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
GRAIL is included in 4 Expert Collections, including Digital Health 150.
Digital Health 150
300 items
The most promising digital health startups transforming the healthcare industry
Digital Health
10,553 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Precision Medicine Tech Market Map
160 items
This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.
Oncology Tech
457 items
This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.
GRAIL Patents
GRAIL has filed 134 patents.
The 3 most popular patent topics include:
- Molecular biology
- DNA
- Genetics
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/30/2018 | 8/15/2023 | Molecular biology, Genetics, Bioinformatics, DNA, Genomics | Grant |
Application Date | 11/30/2018 |
|---|---|
Grant Date | 8/15/2023 |
Title | |
Related Topics | Molecular biology, Genetics, Bioinformatics, DNA, Genomics |
Status | Grant |
Latest GRAIL News
Aug 26, 2023
Grail partnership latest step for broader access to multicancer tests Study to evaluate community outreach strategies for increasing early cancer screening in diverse populations, follows similar deal by Exact Sciences in June By Karen Tkach Tuzman, Director of Biopharma Intelligence August 25, 2023 7:09 PM UTC With real-world data becoming key for understanding the clinical utility of multicancer early detection (MCED) tests, evaluating the blood tests in diverse populations and care settings is critical. Non-profit partnerships announced this half by Grail and Exact Sciences aim to build that understanding by bringing the companies’ tests to underserved populations. In the absence of FDA approval and widespread reimbursement, real-world use of the cell-free DNA (cfDNA)-based Galleri MCED test from the Grail LLC unit of Illumina Inc. (NASDAQ:ILMN), which is marketed via the laboratory-developed test (LDT) pathway, is primarily limited to those who can afford the $949 price tag. ... BCIQ Company Profiles
GRAIL Frequently Asked Questions (FAQ)
When was GRAIL founded?
GRAIL was founded in 2016.
Where is GRAIL's headquarters?
GRAIL's headquarters is located at 1525 O'Brien Drive, Menlo Park.
What is GRAIL's latest funding round?
GRAIL's latest funding round is Acquired.
How much did GRAIL raise?
GRAIL raised a total of $2.005B.
Who are the investors of GRAIL?
Investors of GRAIL include Illumina, ARCH Venture Partners, Public Sector Pension Investment Board, CPP Investments, Qiming Venture Partners and 28 more.
Who are GRAIL's competitors?
Competitors of GRAIL include Owlstone Medical, Beacon Biomedical, Huna, ErleaDx, Freenome and 16 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare GRAIL to Competitors
Freenome uses computational biology and machine learning techniques to detect cancer in its early and treatable stages. It detects cancer at an early stage through a routine blood draw and uses a proprietary algorithm method for systematized early detection. It was founded in 2014 and is based in South San Francisco, California.
20/20 GeneSystems has developed, validated, and undergone clinical testing of a blood test for the early detection of lung cancer. The test measures a panel of tumor biomarkers and utilizes a proprietary algorithm to combine the biomarker values to generate a unitary risk score.
Owlstone Medical is a diagnostics company developing a breathalyzer for disease detection. It offers a breath biopsy platform to enable early detection across multiple cancers and other related conditions. The company was founded in 2004 and is based in Cambridge, U.K.
Liquid Genomics monitors patient therapy via blood-based molecular testing. Blood based testing is used to detect and quantify cancer gene mutations with high sensitivity using Digital PCR and or Allele Specific Blocker PCR for blood or tissue.
Accuragen has developed a high-sensitivity next-generation sequencing-based system for the detection of cancer mutations in minuscule concentrations of circulating cell-free DNA (cfDNA) in blood. The Company's technology addresses the significant barriers associated with harnessing the information contained in cfDNA by combining proprietary techniques in molecular biology and computational algorithm for error suppression. With Accuragen's technology, nanogram quantities of highly-fragmented cfDNA can be amplified more than 1000-fold, and a panel of tens to hundreds of cancer-related genes can be screened with a sensitivity at the single-digit molecular level.
OncoTAB's technology was used to develop a blood test, Agkura Personal Score, which aids breast cancer detection in women with dense breast tissue.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
